Sunitinib is a multi-kinase inhibitor, targeting VEGFR1,2,3 and PDGFRα,β, which reduces angiogenesis, resulting in diminished oxygen supply to cancer cells, thereby inhibiting cancer cell growth (40). This evidence concerns the gene PDGFRA and cancer.